Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors

BACKGROUND: Monoamine oxidase inhibitors (MAOIs) are being developed for major depressive disorder, Alzheimer’s, and Parkinson’s Disease. Newer MAOIs have minimal sensitivity to tyramine, but a key limitation for optimizing their development is that standards for in vivo monoamine oxidase-A (MAO-A)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Neuropsychopharmacol
Autors principals: Chiuccariello, Lina, Cooke, Robert G, Miler, Laura, Levitan, Robert D, Baker, Glen B, Kish, Stephen J, Kolla, Nathan J, Rusjan, Pablo M, Houle, Sylvain, Wilson, Alan A, Meyer, Jeffrey H
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4772270/
https://ncbi.nlm.nih.gov/pubmed/26316187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ijnp/pyv078
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars